Metamizol

Metamizole sodium, the active ingredient in Metamizol, is a pyrazolone non‑opioid analgesic presented as an oral tablet for oral use. It is employed to relieve moderate to severe pain and to reduce fever in adult patients. The medication is commonly prescribed when other analgesics are insufficient.

GNH USA supplies Metamizol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across EU and global markets.

Metamizol is a non‑opioid analgesic and antipyretic used in the management of pain and fever.

- Acute pain: provides rapid relief of moderate to severe pain. - Post‑operative pain: helps control discomfort after surgical procedures. - Fever: reduces elevated body temperature in adults. - Colicky abdominal pain: alleviates visceral pain associated with spasm.

Metamizole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Dizziness: transient light‑headedness. - Hypotension: occasional drop in blood pressure. - Skin rash: mild erythema.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Aplastic anemia: bone‑marrow failure. - Stevens‑Johnson syndrome: severe skin reaction. - Anaphylactic shock: acute allergic response.

Before initiating therapy, consider the following safety measures.

- Assess blood counts: monitor complete blood count before and during treatment. - Evaluate renal function: adjust use in patients with renal impairment. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use cautiously in elderly: increased risk of hypotension. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Metamizole can interact with several drug classes; awareness helps prevent complications.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive agents: risk of severe blood dyscrasias. - Combination with sulfonamide antibiotics: increased risk of agranulocytosis. - Co‑administration with anticoagulants: may enhance bleeding tendency.

Moderate Interactions (Monitor Closely): - Interaction with ACE inhibitors: may potentiate hypotensive effects. - Use with other NSAIDs: additive gastrointestinal irritation. - Concomitant corticosteroids: increased risk of ulceration.